Bryan Wagman
Long/short equity, value, growth at reasonable price, industrials

Myriad Genetics Offers A Potential Upside Of More Than 40%


Myriad Genetics (NASDAQ:MYGN) is a company that is developing products that detect risks of disease based on proteins found in a patient's genes. Some of their products can also determine the likelihood that a patient will respond to a drug in a certain way, ensure optimal dosing, and find the chances of disease progression or recurrence. According to the company's website, over one million patients have already benefited from their informative testing. One of the company's primary products is BRACAnalysis, a predictive medicine test that attempts to uncover a patient's risk of getting breast or ovarian cancer. It also offers COLARIS (tests for colorectal and uterine cancer) and MELARIS (tests for melanoma). Myriad Genetics was founded...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details